Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the 17-Year Immune Persistence of a Single Dose of Inactivated Hepatitis A Vaccine
Sponsor: Sinovac Biotech Co., Ltd
Summary
The purpose of this follow-up study is to evaluate the seventeen-year immune persistence of a single dose of inactivated or attenuated alive hepatitis A vaccine in healthy participants.
Official title: The Phase IV, Follow-up Study to Evaluate the 17-year Immune Persistence of a Single Dose of Inactivated or Alive Attenuated Hepatitis A Vaccine in Healthy Chinese Participants in the Parent Trial(PRO-HA-4013 )
Key Details
Gender
All
Age Range
18 Years - 22 Years
Study Type
OBSERVATIONAL
Enrollment
105
Start Date
2026-01-13
Completion Date
2026-03-09
Last Updated
2026-10-02
Healthy Volunteers
Yes
Conditions
Interventions
Inactivated HAV vaccine
Inactivated hepatitis A vaccine developed by Sinovac Biotech Co., Ltd, per dose containing 250 u antigen, one dose administered in the prior trial.
Attenuated live HAV vaccine
Attenuated alive hepatitis A vaccine, per dose containing 6.50 lgCCID50 alive virus, one dose administered in the prior trial.
Locations (1)
Tianjin Center for Disease Control and Prevention
Tianjin, China